|
gptkbp:instanceOf
|
gptkb:drug
cyclin-dependent kinase inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EF02
|
|
gptkbp:bioavailability
|
60-65%
|
|
gptkbp:brand
|
gptkb:Kisqali
|
|
gptkbp:CASNumber
|
1211441-98-3
|
|
gptkbp:chemicalFormula
|
C23H30N8O
|
|
gptkbp:combinationTherapy
|
gptkb:fulvestrant
gptkb:letrozole
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
32 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ribociclib
|
|
gptkbp:indication
|
HER2-negative breast cancer
hormone receptor-positive breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits CDK4/6
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
70%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
neutropenia
|
|
gptkbp:target
|
gptkb:CDK4
gptkb:CDK6
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:Cdk4
gptkb:Serine/threonine-protein_kinase_CDK4
|
|
gptkbp:bfsLayer
|
8
|